SCHEMBL3264793

SCHEMBL3264793

COc1ccc(S(=O)(=O)Nc2ccc(C)cc2Cc2c(F)cccc2F)cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.54
NFE2L2 Q16236 1/20 0.54
LMNA P02545 5/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
ABCB1 P08183 1/20 0.49
ABCC1 P33527 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
ALDH1A1 P00352 5/20 0.47
TP53 P04637 1/20 0.47
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
TSHR P16473 3/20 0.47
PKM P14618 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3246071 0.88 ALDH1A1 (0.61) KEAP1NFE2L2LMNASMN1; SMN2ABCB1
SCHEMBL3254908 0.85 MEP1B (0.50) LMNASMN1; SMN2ALDH1A1TSHRNPSR1
SCHEMBL3254803 0.83 LMNA (0.55) KEAP1NFE2L2LMNASMN1; SMN2ABCB1
SCHEMBL1750305 0.82 LMNA (0.53) KEAP1NFE2L2LMNASMN1; SMN2ABCB1
SCHEMBL3250123 0.81 MAPK1 (0.60) KEAP1NFE2L2LMNASMN1; SMN2FFAR4
SCHEMBL3256160 0.77 MEP1B (0.50) LMNAALDH1A1TSHRNPSR1HSD17B10
SCHEMBL3253072 0.76 MEP1B (0.52) LMNAALDH1A1TSHRKMT2A
SCHEMBL3253418 0.75 MAPT (0.42) TP53TSHRPKMMEN1KMT2A
SCHEMBL3255576 0.75 HCRTR2 (0.44) ALDH1A1TP53TSHRPKMNPSR1
SCHEMBL4872824 0.74 HCRTR1 (0.42) KEAP1NFE2L2ALDH1A1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 KEAP1 3317/4885NFE2L2 2700/4885LMNA 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.